Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. Droia invests in novel science and innovative approaches to bring promising drug candidates to patients, and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. Droia has an in-house team of experts and drug development professionals who follow the portfolio companies closely and provide hands-on support. Droia invests in early financing rounds and incubates new companies. Operating from Luxembourg and Belgium, Droia invests globally.
Location: Belgium, Flemish Brabant, Meise
Employees: 11-50
Founded date: 2011
Investment Type: Venture Capital
Portfolio 25
| Date | Name | Website | Total Raised | Location |
| 10.03.2026 | Hillstar B... | hillstarbio.com | $67M | United Sta... |
| 25.12.2025 | Protego Bi... | protegobio.com | $130M | - |
| 11.09.2024 | Alesta The... | alestatherapeutics.com | $66.94M | - |
| 10.01.2024 | Vaderis Th... | vaderis.com | $152M | Switzerlan... |
| 01.12.2023 | Hyku Biosc... | hykubiosciences.com | - | United Sta... |
| 02.09.2022 | Actio | actiobio.com | - | United Sta... |
| 06.08.2022 | vicinitastx.com | - | United Sta... | |
| 24.07.2022 | Mahzi | mahzi.com | - | Costa Rica |
| 12.12.2021 | Ambagon Th... | ambagontx.com | $84.91M | United Sta... |
| - | Muna Thera... | munatherapeutics.com | $73M | Denmark, C... |
Show more
Persons 40
| Date | First Name | Last Name | Title | Location | |||
| - | Pauline | De Zeeuw | Associate | - | - | - | |
| - | Jo | Bury | Investment... | - | - | - | |
| - | Sergio | Quezada | Investment... | - | - | - | |
| - | Dan | Nomura | Investment... | - | - | - | |
| - | An | Steensels | Scientific... | - | - | - | |
| - | Willem-Jan | Wollants | Scientist ... | - | - | - | |
| - | Rez | Halse | Partner | - | - | - | |
| - | Kathleen | Sonck | Principal ... | - | - | - | |
| - | Dieter | Petit | Senior Ass... | - | - | - | |
| - | Luc | Verelst | Founder &a... | - | - | - |
Show more
Mentions in press and media 7
| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing Tue, Aug 11, 2026 13:00 CET Report this content EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding. The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing | Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 18.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 18.05.2021 | Hummingbird Bioscience : Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 17.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing |